NCT05766605 is a Phase 3 clinical trial of Oxaliplatin in Hepatocellular Carcinoma Resectable, sponsored by Zhujiang Hospital.

Who is sponsoring NCT05766605?

NCT05766605 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT05766605?

Interventions in NCT05766605: Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed.

What condition does NCT05766605 study?

NCT05766605 studies Hepatocellular Carcinoma Resectable.

Is NCT05766605 still recruiting?

NCT05766605 is currently status unknown. Last updated 13 March 2023.

Last reviewed 2023-03-13 · How we verify

NCT05766605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Status unknown Phase 3 Last updated 13 March 2023

What this trial tests

Phase 3 trial testing Oxaliplatin in Hepatocellular Carcinoma Resectable in 90 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2026

30 January 2026

Quick facts

Lead sponsor	Zhujiang Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 January 2023
Primary completion	1 January 2026
Estimated completion	30 January 2026
Sites	1 location across China

Drugs / interventions tested

Oxaliplatin (Oxaliplatin) — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →
Lobaplatin
Cisplatin (cisplatin) — full drug profile →
Oxaliplatin, Leucovorin, fluorouracil
Lobaplatin, Raltitrexed — full drug profile →

Conditions studied

Hepatocellular Carcinoma Resectable — all drugs for Hepatocellular Carcinoma Resectable →

Sponsor

Zhujiang Hospital

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma Resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Oxaliplatin

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma Resectable

Currently open trials in the same condition.

NCT06157060 — Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05766605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 13 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05766605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing